Pharmaceutical

RegenxBio touts positive data for rare disease drug RGX-121

RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time gene therapy treatment for Hunter syndrome.

Sep 4, 2024 - 04:00
RegenxBio touts positive data for rare disease drug RGX-121
RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time gene therapy treatment for Hunter syndrome.
Read the original article

Tags:

Previous Article

FDA grants fast track status to Innovent’s IBI363 for melanoma

Next Article

Ocaliva approval in Europe withdrawn following data re-assessment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Dana-Farber, in break with Brigham and Women’s, will build new cancer center with Beth Israel

STAT+: Dana-Farber, in break with Brigham and Women’s, ...

Sep 14, 2023

Risk adjusted net present value: What is the current va...

Jul 2, 2024

How did hiring in the US pharma industry perform in Q3 ...

Oct 19, 2023